Locations:
Search IconSearch
April 4, 2018/Cancer/News & Insight

Social Media and Journal Clubs: The Ultimate Peer Review?

An oncologist weighs in

social-media_650x450

ByAaron Gerds, MD

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

The Cotton Club, The Breakfast Club and journal club. Like other legendary clubs, journal club has centered around an in-person gathering to facilitate the exchange of commentary and ideas on a given topic. The critical evaluation of recent articles conducted in journal clubs serves as a building block for medical education, evidence-based guidelines and quality improvement initiatives. From residency training, I have very vivid — dare I say fond? — memories of journal club at Hines VA Hospital getting into the nitty gritty of numbers needed to treat with then Chairman Brian Schmitt, MD, MPH. For the past 180 years, from Sir James Paget to Gordon Guyatt, MD, MSc, journal clubs have been steadfast with a very gradual evolution, but the technology revolution is shaking things up.

Social media, including Twitter, has changed the way we communicate. In addition to focused composition and the introduction of emoji, it has also eliminated distance and time. Discussions including thousands can be had instantly across the globe. It has been argued that social media has dumbed down discourse, reducing it to a series of likes or retweets. Despite its limitations, it can be a powerful tool in the appraisal of the medical literature.

With most manuscripts posted on publishers’ websites well in advance of print, the peer review process can occur almost instantaneously. Social media also enables the readership to interact directly with the authors.

With such a large volume of users, critiques presented and validated are essentially crowdsourced, and conversely, individuals can provide insight on how local context may affect the application of results in their own practice. Social media invites its users to come off the bench and get into the game, identifying quality and refuting misinterpretation by a simple post for many, with others taking the next step into content creation. One key element yet to be clarified as things move forward is how these contributions will be measured and how faculty will get academic credit for participating in online forums.

Advertisement

While time will tell if Twitter and social media are the ultimate peer review, it is clear that they can be a powerful tool in conducting academic medicine. I wonder if William Osler would share his critiques in 280 characters or less.

Dr. Gerds is a staff physician in the Department of Hematology and Medical Oncology and publishes in medical literature about social media use. Follow him on Twitter @AaronGerds.

Advertisement

Related Articles

Dr. Angelini
December 24, 2025/Cancer/News & Insight
Study Analyzes Direct Oral Anticoagulants Use in Patients with Brain Metastases

Large retrospective study suggests DOACs are safe, effective alternative to low-molecular-weight heparin in complex patient population

Lobular breast cancer cells
December 22, 2025/Cancer/Innovations
Comprehensive Lobular Breast Cancer Program Addresses Often-Misunderstood Disease

Care paths and research initiatives aim to answer unmet clinical needs

Dr. Singh
December 19, 2025/Cancer/Blood Cancers
IDH1 Inhibitor Found Safe and Effective in Rare Precursor to Blood Malignancies

Study shows high rate of hematologic responses, low rate of disease progression

Shahzad Raza, MD
December 18, 2025/Cancer/Blood Cancers
Talquetamab Provides Lifesaving Bridge to CAR T-Cell Therapy

Bispecific antibody bridging therapy deepens durability of BCMA CAR T-cell therapy without overlapping toxicities in patients with relapsed/refractory multiple myeloma

Dr. Raza
December 16, 2025/Cancer/Blood Cancers
Dual Bispecifics May Redefine Management of Extramedullary Myeloma

Phase 2 study brings pivotal advances in treatment efficacy and safety for the most challenging-to-treat population

CAR T-cell therapy
December 15, 2025/Cancer/Blood Cancers
Case Study: Patient Remains Disease Free Five Years After Allogenic CAR T-Cell Therapy

Patient with quadruple refractory multiple myeloma achieves complete response with cell therapy

J. Joseph Melenhorst, PhD
December 12, 2025/Cancer/Blood Cancers
Researchers Identify Predictors of Response to CAR T-Cell Therapy in B-Cell Non-Hodgkin’s Lymphoma

Distinct baseline immune profiles can predict response and resistance to different types of CAR-T cells.

church bus tour
December 9, 2025/Cancer/News & Insight
Novel Community Campaign Increases Venous Thromboembolism Awareness

National Blood Clot Alliance collaborates with faith-based organizations on first-of-its-kind church bus tour

Ad